Arsenic trioxide decreases AKT protein in a caspase-dependent manner

Arsenic trioxide (As 2 O 3 ) is used clinically to treat acute promyelocytic leukemia but is less successful in other malignancies. To identify targets for potential combination therapies, we have begun to characterize signaling pathways leading to As 2 O 3 -induced cytotoxicity. Previously, we desc...

Full description

Saved in:
Bibliographic Details
Published in:Molecular cancer therapeutics 2008-06, Vol.7 (6), p.1680-1687
Main Authors: Mann, Koren K, Colombo, Myrian, Miller, Jr, Wilson H
Format: Article
Language:English
Subjects:
Adaptor Proteins, Signal Transducing - metabolism
AKT
apoptosis
arsenic
Arsenicals - pharmacology
Benzoquinones - pharmacology
Caspase 3 - metabolism
caspase cleavage
Caspases - metabolism
Cell Death - drug effects
Cell Line, Tumor
Drug Resistance, Neoplasm - drug effects
Enzyme Activation - drug effects
Humans
JNK Mitogen-Activated Protein Kinases - metabolism
Lactams, Macrocyclic - pharmacology
Oxides - pharmacology
Proteasome Endopeptidase Complex - metabolism
Protein Binding - drug effects
Proto-Oncogene Proteins c-akt - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Arsenic trioxide (As 2 O 3 ) is used clinically to treat acute promyelocytic leukemia but is less successful in other malignancies. To identify targets for potential combination therapies, we have begun to characterize signaling pathways leading to As 2 O 3 -induced cytotoxicity. Previously, we described the requirement for a reactive oxygen species–mediated, SEK1/c-Jun NH 2 -terminal kinase (JNK) pathway to induce apoptosis. AKT inhibits several steps in this pathway; therefore, we postulated that As 2 O 3 might decrease its activity. Indeed, As 2 O 3 decreases not only AKT activity but also total AKT protein, and sensitivity to As 2 O 3 correlates with the degree of AKT protein decrease. Decreased AKT expression further correlates with JNK activation and the release of AKT from the JNK-interacting protein 1 scaffold protein known to assemble the mitogen-activated protein kinase cascade. We found that As 2 O 3 regulates AKT protein stability without significant effects on its transcription or translation. We show that As 2 O 3 decreases AKT protein via caspase-mediated degradation, abrogated by caspase-6, caspase-8, caspase-9, and caspase-3 inhibitors but not proteosome inhibitors. Furthermore, As 2 O 3 enhances the ability of a heat shock protein 90 inhibitor to decrease AKT expression and increase growth inhibition. This suggests that As 2 O 3 may be useful in combination therapies that target AKT pathways or in tumors that have constitutively active AKT expression. [Mol Cancer Ther 2008;7(6):1680–7]
ISSN:1535-7163
1538-8514
DOI:10.1158/1535-7163.MCT-07-2164